Grafa News and Videos — Page 247

SLB (NYSE:SLB) announced that it has been awarded four integrated well construction contracts by Saudi Aramco to support oil and gas development projects across the Kingdom of Saudi Arabia.

Mobix Labs (NASDAQ:MOBX) announced that it expects fiscal fourth-quarter 2026 revenue to exceed the midpoint of its previous guidance range as demand improves across its wireless systems and connectivity businesses.

Pasqal (NYSE:PSQL) reported first-half 2026 revenue of €4.9 million for the six months ended June 30, 2026, representing a 14% increase compared with the prior-year period.

Acadia Pharmaceuticals (NASDAQ:ACAD) announced Phase 3-enabling topline results from the Phase 2 portion of its ongoing RADIANT clinical trial program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).

Redwire Corporation (NYSE:RDW) announced that it has been selected by Space Systems Command as one of 15 vendors awarded a multiple-award indefinite-delivery/indefinite-quantity (IDIQ) contract for the National Space Test and Training Complex Innovative Technology and Engineering – Space Test and Range (NITE-STAR) Capability Development program.

TurboGen (NASDAQ:TRBG) reported a net loss of $4.2 million for the first half of 2026 as the company continued development and commercialization efforts for its microturbine energy systems.

TD SYNNEX (NYSE:SNX) reported record financial results for its fiscal third quarter ended August 31, 2026, with revenue and profitability exceeding the company’s expectations.

Darden Restaurants (NYSE:DRI) reported first-quarter fiscal 2027 sales of $3.2 billion for the period ended August 30, 2026, representing a 5.1% increase compared with the prior-year quarter.

BlackBerry (NYSE:BB) reported second-quarter fiscal 2027 revenue of $163.3 million for the three months ended August 31, 2026, representing a 26% increase compared with the prior-year period.

Merck (NYSE:MRK) announced topline results from the pivotal Phase 2b/3 BRUNELLO trial evaluating remigromig (MK-3000, formerly EYE103) in adults with diabetic macular edema (DME).